Download PDF
Thromb Haemost 1986; 56(02): 133-136
DOI: 10.1055/s-0038-1661626
Original Article
Schattauer GmbH Stuttgart

The Fibrinolytic System in Experimental Prostate Tumor[*]

Hamid Al-Mondhiry
The Departments of Medicine, Surgery, and Behavioral Sciences, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA
,
Joseph Drago
The Departments of Medicine, Surgery, and Behavioral Sciences, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA
,
Mary J Bartholomew
The Departments of Medicine, Surgery, and Behavioral Sciences, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA
› Author Affiliations
Further Information

Publication History

Received 14 February 1986

Accepted 25 June 1986

Publication Date:
26 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Hypofibrinogenemia and disseminated intravascular coagulation are common events in patients with metastatic prostate carcinoma. This study tests the hypothesis that prostate tumor growth and metastasis is associated with sustained activation of fibrinolysis secondary to increased release of plasminogen activator. We implanted an androgen-insensitive prostate tumor into an inbred strain of rats and serially measured plasminogen, plasminogen activator, plasmin and fibrinogen. Control groups included animals without tumor and a group implanted with transitional cell bladder carcinoma, a locally infiltrating tumor not usually associated with hemostatic complications. Our results showed a significant and steady rise in plasma plasminogen activator, plasmin and fibrinogen levels in animals implanted with prostate cancer. This, however, is not specific for prostate tumor. Similar, perhaps more profound changes were noted in animals implanted with the transitional cell carcinoma.

Key words

Fibrinolysis - Prostate tumor

* Supported in part by the American Cancer Society Grant # 417-67 HY.


 

  • References

  • 1 Tagnon HJ, Whitmore Jr WF, Shulman NR. Fibrinolysis in metastatic cancer of the prostate. Cancer 1952; 5: 9-12
    CrossrefPubMedGoogle Scholar
  • 2 Rasmussen J, Alberchtsen OK. Characterization of the fibrinolytic components of the human prostate. Scand J Clin Lab Invest 1960; 12: 261-268
    CrossrefPubMedGoogle Scholar
  • 3 Straub PW. Chronic intravascular coagulation.Clinical spectrum and diagnostic criteria with special emphasis on metabolism, distribution and localization of 131I-fibrinogen. Acta Med Scand (suppl) 1971; 526: 1-95
    PubMedGoogle Scholar
  • 4 Mertins BF, Green LF, Bowie EJW, Elveback LR, Owen jr CR. Fibrinolytic split products (FSP) and ethanol gelation test in preoperative evaluation of patients with prostatic disease. Mayo Clinic Proc 1974; 49: 642-646
    PubMedGoogle Scholar
  • 5 Owen Jr CA, Bowie EJW. Chronic intravascular coagulation and fibrinolysis (ICF) syndromes (DIC). Semin Thromb Hemostasis 1977; 3: 268-290
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Al-Mondhiry H. Disseminated intravascular coagulation, experience at a major cancer center. Thromb Diath Haemorrh 1975; 34: 181-193
    PubMedGoogle Scholar
  • 7 Pergament ML, Swaim WR, Blackard CE. Disseminated intravascular coagulation in the urologic patient. J Urol 1976; 116: 1-7
    CrossrefPubMedGoogle Scholar
  • 8 Goldenberg SL, Fenster HN, Perler Z, McLouglin MG. Disseminated intravascular coagulation in carcinoma of prostate: role ofestrogen therapy. Urology 1983; 22: 130-132
    CrossrefPubMedGoogle Scholar
  • 9 Drago JR, Goldman LB, Gerswhin ME. Chemotherapeutic & hormonal considerations of the Nb rat prostatic adenocarcinoma model. Models for Prostatic Cancer. In Prog, in Clin & Biol Res. Ser. Murphy GR. (ed) Vol 37 325-363 Alan K Liss; New York, NY: 1980
    Google Scholar
  • 10 Drago JR, Goldman LB, Maurer RE, Eckels DD, Gershwin ME. Histology, histochemistry, and acid phosphatase of noble (Nb) rat prostate adenocarcinoma and treatment of an androgen-dependent Nb rat prostate adenocarcinoma. J Natl Cancer Inst 1980; 64: 931-937
    PubMedGoogle Scholar
  • 11 Drago JR, Al-Mondhiry H. The effect of prostaglandin modulators on prostate tumor growth and metastasis. Anticancer Res 1984; 4: 391-394
    PubMedGoogle Scholar
  • 12 Drago JR, Curley RM. Cytometrically monitored neoplastic progression in the Nb bladder cancermodel: selective proliferation of variant subpopulations. J Urol 1985; 134: 1024-1028
    CrossrefPubMedGoogle Scholar
  • 13 Winer BJ. Statistical principles in experimental design. 2nd Ed McGraw Hill Book Co.; New York: 1971
    Google Scholar
  • 14 Latallo ZS, Teisseyre E, Lopaciuk S. Assessment of fibrinolytic system with use of chromogenic substrate. Haemostasis 1978; 7: 150-154
    PubMedGoogle Scholar
  • 15 Stevens DJ, Sanfellipo MJ. Evaluation of three methods for plasma fibrinogen determination. Amer J Clin Pathol 1973; 59: 182-187
    PubMedGoogle Scholar
  • 16 Zar JH. Binomial distribution. In: Biostatistical Analysis. 292 Prentice Hall; Englewood Cliffs, NJ: 1974
    Google Scholar
  • 17 Peck SD, Reiquam CW. Disseminated intravascular coagulation in cancer patients: supportive evidence. Cancer 1973; 31: 1114-1119
    CrossrefPubMedGoogle Scholar
  • 18 Tagnon HJ, Whitmore jr WF, Schulman P, Kravitz SC. The significance of fibrinolysis occurring in patients with metastatic cancer of the prostate. Cancer 1953; 6: 63-67
    CrossrefPubMedGoogle Scholar